Viatris (VTRS)

Owns it on a short leash. It has low growth. He likes the set up, but they need to focus on shareholder value. Trades at only 7-8x PE. Still likes it.

It was spun out of Pfizer. It doesn't make their list. It is kind of a small cap with a small footprint. In the health care field only look for companies on sale.

Proof that not every stock he buys goes up ;)  He's held for years. Recent earnings were weak, and stock fell ~15%. Generating significant free cashflow, which now will be used to buy back shares incredibly cheaply. It's the best use of capital at this time. FDA investigation in one of their plants, costing about $300-400M in EBITDA. Yield is 4+%.

Has owned it a few years and it's only starting to perform recently after earnings and a share buyback announcement. Very cheap at 5x PE. Stable revenues and lots of free cash flow, and pays a 4% dividend. He targets $20.

It is a pharma company trading at 5X earnings. It is buying back stock, as much as 5% and has a slew of new products.

Great free cashflow, more than covers the 4% yield. Cheap PE at 4x earnings. Q2 results coming out in early August, where a couple of divestitures will be announced. Awaiting stock buyback. Paying down debt, making acquisitions. $12B market cap, but not well followed.

Stock's done nothing for him except pay a 4% dividend. A couple of more asset sales to go next quarter. He'd love it if they took the cash, paid down debt, and bought back shares. But management keeps making acquisitions, riskier. Trades at 3-4x earnings.

Share price flat, but owns shares.
Excellent business within healthcare sector.
Getting into new business lines.
4% dividend yield with lots of free cash flow.
Share buybacks good for shareholders.
Trading at 4x earnings.

Product of recent merger of two separate pharma business'.
New CEO - remains to be seen whether he will preform.
Would like to see stabilization on business before investing.
Too early to invest. 

It is the cheapest stock in their portfolio at 4X earnings, a pharma company formed by a joint venture. Its investment grade bond issues are in rock solid shape. It sold a division for $2 billion and will use the cash for a couple of acquisitions in eye wear and to buy back stock. There are potential sales of other smaller divisions so there could be more buybacks plus paying down debt. The dividend yield is 4.1%. Has a low price due to a couple of disappointing quarters but numbers have been solid since. Also revenues have been flat-lining.
Buy 4   Hold 10   Sell 0

Global healthcare, mix of branded drugs and generics. Drug business has had a good run, but there's going to be significant pushback on the outsized profits, both globally and in the US. He prefers medical devices.